This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Discovery Labs

I asked Chrisian Itin, Micromet's CEO, about any changes to the company's relationship with AstraZeneca during a call Thursday morning. He wouldn't answer the question, stating only that as of now, the arrangement with AstraZeneca remains as it was.

It's hard to say what this all means. If blinatumomab were a great drug in the making, why did AstraZeneca relinquish North American rights last March?

Perhaps AstraZeneca's pipeline priorities changed and it could no longer devote resources to the drug. That's entirely possible, but then why would AstraZeneca also decide to accept just $6 million to further give up an option to reacquire the rights to the drug if it did turn out to be a big moneymaker sometime in the future?

If Micromet does buy out AstraZeneca completely, the company will own unencumbered worldwide rights to blinatumomab, which is being developed right now in two hematologic cancer indications. The company also has other drugs in earlier stages of development, some partnerned with other companies, and a platform to generate new antibodies.

Perhaps Wednesday night's money raise and the complete divorce from AstraZeneca is a precursor to a newer and more lucrative partnership or even an acquisition. Or, perhaps not.


A correction and further comment: When I filmed this week's video on Biocryst Pharmaceuticals (BCRX - Get Report), I inadvertently described the company's flu drug as a vaccine. Peramivir is an antiviral used to treat patients infected with the flu virus; it is not a vaccine used to protect people from getting infected in the first place.

3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CTIC $1.96 0.00%
BCRX $10.35 0.00%
BDSI $9.26 0.00%
DSCO $1.24 0.00%
INO $10.35 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs